Stefano Baldoni
Overview
Explore the profile of Stefano Baldoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
525
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lanuti PhD P, Guardalupi F, Corradi PhD G, Florio PhD R, Brocco MD PhD D, Veschi PhD S, et al.
Blood Adv
. 2025 Feb;
PMID: 39903124
Chimeric Antigen Receptor (CAR) T cell-derived Extracellular Vesicles (EVs) might represent a new therapeutic tool for boosting CAR-T cell antileukemic effects. Here, a cohort of 22 patients infused with CD19.CAR-T...
2.
Ranalli P, Baldoni S, Bruno D, Di Ianni M
Mediterr J Hematol Infect Dis
. 2024 Sep;
16(1):e2024067.
PMID: 39258184
No abstract available.
3.
Liberatore C, Fioritoni F, Natale A, Montanaro G, La Barba G, Passeri C, et al.
EJHaem
. 2023 Nov;
4(4):1152-1156.
PMID: 38024589
The coexistence of chronic myeloid leukemia (CML) and multiple myeloma (MM) is a rare clinical condition. By means of FISH and molecular analysis on both sorted CD138 plasma cells and...
4.
Pennese E, Salutari P, Carriero L, Restuccia F, De Filippis A, De Luca G, et al.
Front Immunol
. 2023 Oct;
14:1272798.
PMID: 37841271
CAR-T therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies. Patients who are receiving such therapy are susceptible to an increased incidence of infections due to post-treatment immunosuppression. The need...
5.
Barcelos E, Rompietti C, Adamo F, Dorillo E, De Falco F, Del Papa B, et al.
Front Oncol
. 2023 Oct;
13:1218989.
PMID: 37817771
Introduction: Constitutive activation of -wild-type (NT1-WT) signaling is associated with poor outcomes in chronic lymphocytic leukemia (CLL), and mutation (c.7541_7542delCT), which potentiates NOTCH1 signaling, worsens the prognosis. However, the specific...
6.
Moia R, di Bergamo L, Talotta D, Bomben R, Forestieri G, Spina V, et al.
Br J Haematol
. 2023 Aug;
203(3):416-425.
PMID: 37580908
Here we evaluated the epigenomic and transcriptomic profile of XPO1 mutant chronic lymphocytic leukaemia (CLL) and their clinical phenotype. By ATAC-seq, chromatin regions that were more accessible in XPO1 mutated...
7.
Adamo F, Barcelos E, De Falco F, Dorillo E, Rompietti C, Sorcini D, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509279
Background: Chronic lymphocytic leukemia (CLL) is an incurable disorder associated with alterations in several pathways essential for survival and proliferation. Despite the advances made in CLL therapy with the new...
8.
Guardalupi F, Sorrentino C, Corradi G, Giancola R, Baldoni S, Ulbar F, et al.
Leukemia
. 2023 Jun;
37(7):1572-1575.
PMID: 37286785
No abstract available.
9.
De Falco F, Rompietti C, Sorcini D, Esposito A, Scialdone A, Baldoni S, et al.
Cell Death Dis
. 2022 Sep;
13(9):755.
PMID: 36050315
NOTCH1 alterations have been associated with chronic lymphocytic leukemia (CLL), but the molecular mechanisms underlying NOTCH1 activation in CLL cells are not completely understood. Here, we show that GSK3β downregulates...
10.
Sportoletti P, De Falco F, Del Papa B, Baldoni S, Guarente V, Marra A, et al.
Int J Mol Sci
. 2021 Jul;
22(13).
PMID: 34206399
Key features of chronic lymphocytic leukemia (CLL) are defects in the immune system and the ability of leukemic cells to evade immune defenses and induce immunosuppression, resulting in increased susceptibility...